Literature DB >> 33310048

Sacubitril/valsartan treatment relieved the progression of established pulmonary hypertension in rat model and its mechanism.

ShuangYe Liu1, Ya Wang1, Shuai Lu2, Jing Hu1, XiaoHui Zeng1, WenHu Liu1, Yan Wang3, ZhaoHui Wang4.   

Abstract

AIMS: Pulmonary hypertension (PH) is a fatal disease identified by progressive elevated pulmonary arterial pressure, which neurohormonal activation is a notable contributor to its development. Sacubitril/valsartan is a complex of sacubitril [via enhancing the natriuretic peptide (NP) system] and valsartan [via blocking the renin-angiotensin-aldosterone system (RAAS)]. Regulation of the two neurohormonal system had been shown to attenuate PH. This study was to explore the role of sacubitril/valsartan in both monocrotaline (MCT)-induced and hypoxia-induced rat models and the underlying mechanism. MAIN
METHODS: The rats were treated with MCT or hypoxic environment for 14 days, after that sacubitril/valsartan were given for another 14 days. Hemodynamic measurements and histological assessments were performed. The expression of NPs was measured using RT-PCR and ELISA, while the protein level of natriuretic peptide receptors (NPRs) and AT1 receptor were detected by western blot, the concentrations of cGMP, IL-1β, IL-6, TNF-α and TGF-β1 were tested by ELISA. KEY
FINDINGS: We found that sacubitril/valsartan significantly improved the hemodynamic and histological data of two PH models. Sacubitril/valsartan suppressed the protein expression of AT1 receptor (P < 0.05). The intervention increased the expression of ANP and CNP (P< 0.05) and therefore upregulated the protein expression of NPRs (P < 0.05), raised the concentration of cGMP (P < 0.05). In addition, the treatment reduced the concentration of IL-1β, IL-6 and TNF-α (P < 0.05) but have no effects on TGF-β1. SIGNIFICANCE: Sacubitril/valsartan alleviated PH in MCT-induced and hypoxia-induced rat models by inhibiting the activated RAAS, promoting ANP/NPR-A/cGMP and CNP/NPR-B/cGMP pathway, restoring the NPR-C signaling and the anti-inflammatory effects.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Natriuretic peptide system; Pulmonary hypertension; Renin-angiotensin-aldosterone system; Sacubitril/valsartan; cGMP

Mesh:

Substances:

Year:  2020        PMID: 33310048     DOI: 10.1016/j.lfs.2020.118877

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  2 in total

Review 1.  Recent Advances and Future Prospects of Treatment of Pulmonary Hypertension.

Authors:  Adrija Hajra; Israel Safiriyu; Prasanth Balasubramanian; Rahul Gupta; Selia Chowdhury; Abhishek J Prasad; Akshay Kumar; Deepak Kumar; Baseer Khan; Roberta S F Bilberry; Ankit Sarkar; Paras Malik; Wilbert S Aronow
Journal:  Curr Probl Cardiol       Date:  2022-04-29       Impact factor: 16.464

2.  Effects of Valsartan on LN, FN, MDA, Renal Tissue Fibrosis, and Inflammatory Infiltration in DN Rats.

Authors:  Yongting Qin; Gugangzhi Li; Juan Chen; Shuangli Qin; Shizhen Wang; Shanshan Chen
Journal:  Contrast Media Mol Imaging       Date:  2022-08-04       Impact factor: 3.009

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.